OUTCOMES OF HEPATITIS B AND TUBERCULOSIS SCREENING IN A COHORT OF PATIENTS ON BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS) FOR RHEUMATIC DISEASE AT A MELBOURNE PUBLIC HOSPITAL

被引：0
|
作者：
Pourhadi, H. [1 ]
Johnson, A. [1 ]
Foote, A. [1 ]
机构：
[1] Northern Hlth, Rheumatol, Epping, NSW, Australia
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Vaccination/Immunization; bDMARD; Quality of care;
D O I：
10.1136/annrheumdis-2023-eular.5494
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB1618
引用
收藏
页码：2043 / 2044
页数：2
相关论文
共 50 条
  • [1] VACCINATION UPTAKE IN A COHORT OF PATIENTS ON BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS) AT A MELBOURNE PUBLIC HOSPITAL
    Pourhadi, Hedayat
    Johnson, Amy
    Foote, Andrew
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 51 - 52
  • [2] TREATMENT WITH BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS) FOR RHEUMATIC DISEASE AT A MELBOURNE PUBLIC HOSPITAL: BASELINE CHARACTERISTICS AND PRE-TREATMENT SCREENING
    Pourhadi, Hedayat
    Foote, Andrew
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 38 - 38
  • [3] Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B
    King, L. K.
    Lee, A.
    Anandacoomarasamy, A.
    INTERNAL MEDICINE JOURNAL, 2012, 42 (05) : 523 - 531
  • [4] VACCINATION UPTAKE IN A COHORT OF PATIENTS ON BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (BDMARDS) AT A MELBOURNE PUBLIC HOSPITAL
    Pourhadi, H.
    Johnson, A.
    Foote, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 2139 - 2139
  • [5] Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis
    Akter, Ripa
    Maksymowych, Walter P.
    Martin, M. Liam
    Hogan, David B.
    CANADIAN GERIATRICS JOURNAL, 2020, 23 (02) : 184 - 189
  • [6] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [7] Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    Drakopoulou, Maria
    Soulaidopoulos, Stergios
    Oikonomou, George
    Tousoulis, Dimitrios
    Toutouzas, Konstantinos
    CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (05) : 488 - 506
  • [8] Pharmacogenetics of disease-modifying anti-rheumatic drugs
    Tanaka, E
    Taniguchi, A
    Urano, W
    Yamanaka, H
    Kamatani, N
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (02): : 233 - 247
  • [9] Disease-modifying anti-rheumatic drugs - Cyclosporin
    Chaudhuri, K
    Torley, H
    Madhok, R
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (09): : 1016 - 1021
  • [10] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Xerxes Pundole
    Natalia V. Zamora
    Harish Siddhanamatha
    Heather Lin
    Jean Tayar
    Leung Cheuk Hong
    Liang Li
    Maria E. Suarez-Almazor
    Clinical Rheumatology, 2020, 39 : 787 - 794
12345